Persistent elevation of VEGF and prostacyclin following poor cardiopulmonary adaptation to high altitude

Wilderness and Environmental Medicine

Volumn 20, Issue 1, 2009, Pages 97-98

  White, Michel ^a   Touyz, Rhian ^a   Tessier, Yves ^a   Van Le, Vy ^a   Ross, Heather ^a   Sirois, Martin G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ANGIOPOIETIN 2; BIOLOGICAL MARKER; INTERLEUKIN 6; PROSTACYCLIN; VASCULOTROPIN;

ADAPTATION; ADULT; ALTITUDE; ALTITUDE DISEASE; ANGIOGENESIS; BOLIVIA; CARDIOPULMONARY FUNCTION; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATION; LETTER; MALE; MOUNTAINEERING; OXIDATIVE STRESS; SYMPTOMATOLOGY;

EID: 63649084059     PISSN: 10806032     EISSN: None     Source Type: Journal    
DOI: 10.1580/08-WEME-LE-248.1     Document Type: Letter

References (6)

1. Tissot van Patot MC, Leadbetter G, Keyes LE, et al. Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness. J Appl Physiol. 2005;98:1626-1629.
2. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol. 2007;49:1015-1026.
3. 2 balance: pathophysiological and therapeutic implications. Br Med Bull. 1983;39:271-276.
4. Lake Louise Consensus on The Definition and Quantification of Altitude Illness. In: Hypoxia and Mountain Medicine. Sutton JR, Coates G, Houston CS, eds. Burlington, VT: Queen City Press; 1992:327-330.
5. Hackett PH, Renne D. The incidence, importance and prophylaxis of acute mountain sickness. Lancet. 1976;2:1149-1154.
6. Dorward DA, Thompson AAR, Baillie JK, MacDougall M, Hirani N. Change in plasma vascular endothelial growth factor during onset and recovery from acute mountain sickness. RespirMed. 2007;101:587-594.